Aptorum Group Limited Announces Results of 2022 Annual General Meeting of ShareholdersBusiness Wire • 12/22/22
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)Accesswire • 11/25/22
Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)Business Wire • 11/25/22
Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price DeficiencyBusiness Wire • 11/18/22
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022Business Wire • 11/08/22
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022Business Wire • 09/30/22
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong KongBusiness Wire • 09/15/22
Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular DiagnosticsBusiness Wire • 09/15/22
Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022Business Wire • 08/26/22
Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022Business Wire • 05/17/22
Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastomaBusiness Wire • 05/02/22
Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business UpdateBusiness Wire • 04/29/22
First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods GrantedBusiness Wire • 04/25/22
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®Business Wire • 04/22/22
Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of NeuroblastomaBusiness Wire • 01/20/22
Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to NeuroblastomaBusiness Wire • 01/18/22
Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel BiomarkersBusiness Wire • 01/10/22